Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis-Reference-Cited by-同舟云学术

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis

Published:2025-04-15 Issue:1 Volume:15 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Sawalha Y.^ORCID,Sarosiek S.^ORCID,Welkie R. L.,Seif S.,Thapa S.,Zanwar S.^ORCID,Cahill K.,Treitman R.,Shah H.,Arora S.,Pongas G.,Winter A.,Major A.^ORCID,Riedell P. A.^ORCID,Palomba M. L.^ORCID,Kapoor P.^ORCID,Grajales-Cruz A.,Shain K. H.,Thomas S. K.,Castillo J. J.^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-025-01271-3.pdf

Reference16 articles.

1. Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, et al. Review consensus treatment recommendations from the tenth international workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020;7:e827–37. https://doi.org/10.1016/S2352-3026(20)30224-6

2. Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, et al. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild-type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015;170:134–8. https://doi.org/10.1111/bjh.13278

3. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017;35:826–33. https://doi.org/10.1200/JCO.2016.70.4320

4. Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, et al. Venetoclax in previously treated waldenström macroglobulinemia. J Clin Oncol. 2022;40:63–71. https://doi.org/10.1200/JCO.21.01194

5. Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, et al. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:e240001. https://doi.org/10.6004/jnccn.2024.0001

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | The Optimal Management of Waldenström Macroglobulinemia;Clinical Lymphoma Myeloma and Leukemia;2025-06